Cisplatin and other platinating agents are some of the most widely used chemotherapy agents. These drugs exert their antiproliferative effects by creating intrastrand and interstrand DNA crosslinks, which block DNA replication. The crosslinks mobilize signaling and repair pathways, including the Rad9-Hus1-Rad1 (9-1-1)•ATR•Chk1 pathway, a pathway that helps tumor cells survive the DNA damage inflicted by many chemotherapy agents. Here we show that Rad9 and ATR play critical roles in helping tumor cells survive cisplatin treatment. Unexpectedly, however, depleting Chk1 with siRNA or inhibiting Chk1 with AZD7762 did not sensitize these cells to cisplatin, oxaliplatin, or carboplatin. Moreover, when Rad18, Rad51, BRCA1, BRCA2, or FancD2 were disabled, Chk1 depletion did not further sensitize the cells to cisplatin. In fact, Chk1 depletion reversed the sensitivity seen when Rad18 was disabled. Collectively, these studies suggest that the pharmacological manipulation of Chk1 may not be an effective strategy to sensitize tumors to platinating agents.
Introduction
The platinum-based chemotherapy drugs cisplatin, carboplatin, and oxaliplatin are among the most active and widely used agents for the treatment of malignancies, including testicular, head and neck, ovarian, lung, colorectal, and bladder cancers (Kelland, 2007) . It is generally accepted that these agents kill tumor cells primarily by creating DNA lesions, which are most cytotoxic during S phase, likely because the lesions are potent inhibitors of DNA replication (Donaldson et al., 1994) .
When a replication fork is stalled by either intra-or interstrand crosslinks, sophisticated repair and signaling pathways are called into action. In the case of bulky adducts such as intrastrand crosslinks (which comprise the majority of platin-induced lesions), the stalled replication fork triggers the monoubiquitylation of PCNA (Lehmann, 2006) . Ubiquitylated PCNA then recruits one or more translesion synthesis (TLS) polymerases, which have active sites that can accommodate bulky lesions, thereby allowing error-prone bypass of the lesion. In contrast, interstrand crosslinks, which account for a few percent of cisplatin-induced DNA lesions but are far more cytotoxic, cannot be simply bypassed. Instead, their repair involves a complex interplay between a series of DNA repair pathways, including the TLS, Fanconi's anemia (FA), and homologous repair (HR) pathways (Dronkert and Kanaar, 2001) . While the complete mechanistic details of how these pathways accomplish this repair remain unknown, it is clear that defects in these pathways dramatically sensitize cells to agents that cause interstrand crosslinks, including the platinating agents (Dronkert and Kanaar, 2001) . interest in pharmacologically targeting this pathway as a means to increase the cytotoxicity of genotoxic cancer therapies, with most of these efforts focused on identifying small molecule inhibitors of Chk1, the most "druggable" component in the signaling pathway. Consistent with that prediction, recent work has shown that Chk1 inhibitors potentiate the activity of nucleoside analogs and topoisomerase I inhibitors in cell lines and xenografts; and these inhibitors are now in early stage clinical trials in combination with gemcitabine and irinotecan (Ashwell and Zabludoff, 2008) .
Although platinating agents are among the most widely used chemotherapy agents, little is known about what checkpoint signaling pathways are activated by these agents or how these pathways affect the survival of tumor cells treated with these agents. To that end, we performed a stepwise analysis and examined the role the 9-1-1•ATR•Chk1 pathway in cells treated with platinating agents to gain insight into which aspects of this signaling pathway are important for tumor cell survival and to assess whether Chk1 plays an important role in facilitating tumor cell survival following treatment with platinating agents.
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GCUCUCUGAUCGUGAUUUA; and FancD2, GGUCAGAGCUGUAUUAUUC. On day 1, siRNA (900 ng) was combined with 12 µL HiPerFect reagent (Qiagen), incubated at room temperature for 5 min, and added to cells in the well for a final siRNA concentration of 30 nM. Transfections were repeated on day 2. On day 3, cells were re-plated in 100-mm tissue culture dishes. On day 4, cells were trypsinized, used to set up clonogenic assays and lysed for immunoblotting. Clonogenic assays were performed as described previously (Karnitz et al., 2005) using 24-h drug treatments.
Cell lysis and immunoblotting were performed as described (Volkmer and Karnitz, 1999) , and blots were developed with SuperSignal West Pico chemiluminescent substrate (Pierce).
Cell cycle analysis. Trypsinized cells were permeabilized with ice-cold 70% ethanol in PBS, stored at -20˚C for 1 h, centrifuged, resuspended in phosphate-buffered saline containing 50 µg/ml propidium iodide and 100 µg/ml RNase, incubated at 30˚C for 30 min, and analyzed by flow microfluorimetry (FACScan, Becton Dickenson).
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Rad9 and ATR depletion sensitizes HeLa cells to cisplatin.
To further evaluate the role of Rad9 and ATR in resistance to cisplatin (and to also demonstrate that the results of a Rad9 deficiency were not specific to mouse ES cells), we analyzed the effects of depleting Rad9 and ATR from HeLa cells using siRNAs (Fig. 1B) . Because we had shown previously that Rad9 and ATR play critical roles in helping tumor cells (including HeLa cells) survive treatment with gemcitabine, a nucleoside analog that disrupts DNA replication (Karnitz et al., 2005) , we also treated the cells with gemcitabine. Depletion of either Rad9 or ATR sensitized HeLa cells to cisplatin (Fig. 1C) as well as gemcitabine (Fig. 1D) , thus demonstrating that these checkpoint proteins play critical roles in facilitating the survival of cisplatin-treated tumor cells. To further probe the role of Chk1 in cisplatin cytotoxicity, we used AZD7762, a small molecule that inhibits both Chk1 and Chk2 with similar potency (Zabludoff et al., 2008) . While this agent dramatically sensitized HeLa cells to gemcitabine ( Fig. 2A) , it did not sensitize the cells to cisplatin (Fig. 2B ). This result suggested that neither Chk1 nor Chk2 plays an important role in helping cells survive cisplatin treatment. Consistent with this finding, co-depletion of Chk1 and Chk2 with siRNAs ( Fig. 2C ) did not sensitize HeLa cells to cisplatin (Fig. 2D ). Taken together, these results demonstrate that while ATR is important for tumor cell survival after treatment with platinating agents, Chk1 is not, even when Chk2 is also depleted.
Cisplatin activates Chk1. In view of the unexpected finding that Chk1 depletion did not sensitize HeLa cells to platinating agents, we asked whether the DNA damage induced This article has not been copyedited and formatted. The final version may differ from this version. (Liu et al., 2000) , was assessed (Fig 3A) . In addition, to demonstrate that the phosphorylated Chk1 was relaying signals to downstream targets, we analyzed Cdc25A, a Chk1 substrate that is targeted for proteasomal degradation after Chk1-mediated phosphorylation. Consistent with previous results, cisplatin induced Chk1 phosphorylation under all conditions tested; and there was a corresponding decrease in the levels of Cdc25A (Fig. 3A , lanes 2-5). As a control for this experiment, we initially treated cells with concentrations of gemcitabine that also reduced clonogenicity by 10% (30 nM) and 90% (100 nM), but we observed nearly undetectable Chk1 phosphorylation (Fig. 3A , lanes 6 and 8, and data not shown); notably, however, a high concentration of gemcitabine (1000 nM) induced robust Chk1 phosphorylation and Cdc25A degradation (Fig. 3A, lane 7) . Taken together, these results suggest that cisplatin -at isotoxic concentrations -is a better inducer of Chk1 phosphorylation than gemcitabine; however Chk1 only plays a role in helping cells survive gemcitabine but not cisplatin treatment.
Depleting Chk1 disrupts the cisplatin-induced S-phase arrest. A major function of
Chk1 following genotoxic stress is to block origin firing and S-phase progression. To assess whether the Chk1 activated in cisplatin-treated HeLa cells was indeed promoting an S phase arrest, we examined the cisplatin-induced cell cycle arrest in control and and U2OS cells, which were derived from a colorectal carcinoma and an osteosarcoma, respectively, were selected for these studies because patients with these tumors are often treated with platinating agents. Consistent with the results for HeLa cells (Fig. 1) , Chk1 depletion did not sensitize either HCT-116 or U2OS cells to cisplatin, whereas both cells lines were sensitized to gemcitabine (Fig. 4A-D) . Similarly, Chk1 depletion did not sensitize HCT-116 cells to oxaliplatin, an agent that is often used to treat colon cancer, or the lung cancer cell line A549 to cisplatin (data not shown). Collectively, these results show that Chk1 does not play a rate-limiting role in preventing the antiproliferative effects of platinating agents in multiple cell types, including cell lines derived from tumors that are routinely treated with these drugs. Disabling DNA repair pathways does not make cisplatin-treated tumor cells reliant on Chk1. We reasoned that Chk1 signaling pathways might assume increased importance if the pathways that repair platinum-induced lesions were disabled. Many of the tumors that are treated with cisplatin harbor defects in repair pathways for cisplatininduced lesions. Thus, if Chk1 depletion sensitized a tumor cell with a defect in a specific repair pathway, then Chk1 inhibitors might be useful to sensitize these tumors to platinating agents. To test this idea, we first depleted HeLa cells of Rad51, BRCA1, Rad18, FancD2, or BRCA2 (supplemental figure 1) , all of which participate in the repair of cisplatin-induced lesions. In all cases, knockdown of any single repair protein increased the sensitivity of the cells to cisplatin (Fig. 5A-E) . When the effects of simultaneously depleting Chk1 with each individual repair protein were examined, we observed that in no case did co-depletion of Chk1 and the repair protein further sensitize the cells to cisplatin. To the contrary, simultaneous depletion of Rad18 or FancD2 with Chk1 rendered cells less sensitive to cisplatin than depletion of Rad18 or FancD2 alone (Fig. 5A and 5E ). Multiple studies have shown that Chk1 depletion and Chk1 inhibitors potently sensitize tumor cells to the damage induced by S phase-active agents such as gemcitabine, hydroxyurea, or 5-fluorouracil (Blasina et al., 2008; Cho et al., 2005; Karnitz et al., 2005; Matthews et al., 2007; Morgan et al., 2006; Robinson et al., 2006) . During S phase, Chk1 contributes to cell survival by blocking the firing of unfired origins of replication, preventing cells from exiting G2, stabilizing stalled replication forks, and regulating DNA repair (Enders, 2008) . Because the intrastrand and interstrand crosslinks caused by cisplatin are also potent inhibitors of DNA replication, we expected that Chk1 would also facilitate tumor cell survival after cisplatin treatment. Surprisingly, however, even though cisplatin provoked robust Chk1 activation and this activation was important in blocking progression through S phase, Chk1 depletion did not sensitize these tumor cell lines to platinating agents.
Such results strongly suggest that not all stalled replication forks require Chk1 to maintain their stability. Moreover, they also indicate that the Chk1-mediated block of origin firing does not contribute to increased cell survival. One possible explanation is that the Chk1-mediated suppression of origin firing is most important when continued replication would actually create additional DNA damage -such as when additional gemcitabine is incorporated into the genome. In contrast, when the damage is preexisting, as with cisplatin, additional origin firing would not incorporate further damage into the genome. This later point is of particular interest since a recent study has shown that the repair of interstrand crosslinks is initiated only when two opposing replication forks converge on the lesion (Raschle et al., 2008) , thus raising the possibility that the repair of these lesions might depend on the activation of additional replication origins.
This article has not been copyedited and formatted. The final version may differ from this version. Chk1, in addition to regulating origin firing and replication fork stability, also positively regulates DNA repair pathways that are important for the repair of interstrand crosslinks in a least two ways. First, Chk1 promotes HR, in part by phosphorylating Rad51 (Huang et al., 2008; Sorensen et al., 2005) . Second, Chk1 phosphorylates FancE , which stimulates the repair of interstrand crosslinks through the FA pathway (Wang, 2007) . Because our results clearly demonstrate that the HR and FA pathways are important in HeLa cells treated with cisplatin, the lack of an effect on cell survival when Chk1 is depleted suggests that Chk1 does not play a major regulatory role in these repair pathways in the cell lines examined.
We also explored the possibility that Chk1 might only become important in cisplatin-treated cells when specific DNA repair pathways were disrupted. This is of particular relevance because tumors often have defective DNA repair pathways, and the defects in these pathways likely contribute to the sensitivity of the tumor to chemotherapy regimens (Garcia and Benitez, 2008; Powell and Kachnic, 2008) . For example, patients with defects in BRCA1 and BRCA2 have better overall responses (including longer survival) to platinum-based therapies (Foulkes, 2006; Sakai et al., 2008) , likely because BRCA1 and BRCA2 play critical roles in repairing the cisplatininduced damage. If Chk1 was important in such cells, then tumors that harbor these defects might be good candidates for clinical trials that combine cisplatin and a Chk1 inhibitor. We did not observe such an outcome. Instead, we found that Chk1 depletion actually reduced the sensitivity of cells with disabled FA (i.e., FancD2) and TLS (i.e.,
Rad18) pathways. Not only do these results further suggest that Chk1 inhibitors might
